Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia and Chronic Liver Disease
Lusutrombopag, an oral small molecule agonist of the thrombopoietin receptor, achieves and maintains target platelet count in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures, researchers report in a phase 3, placebo-controlled trial published in the May issue of Clinical Gastroenterology and Hepatology. The drug caused no significant
Read more